Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue

PLoS One. 2015 Dec 11;10(12):e0144606. doi: 10.1371/journal.pone.0144606. eCollection 2015.

Abstract

Aims: Viral infection is associated with pancreatic beta cell destruction in fulminant type 1 diabetes mellitus. The aim of this study was to investigate the acceleration and protective mechanisms of beta cell destruction by establishing a model of viral infection in pancreatic beta cells.

Methods: Polyinosinic:polycytidylic acid was transfected into MIN6 cells and insulin-producing cells differentiated from human induced pluripotent stem cells via small molecule applications. Gene expression was analyzed by real-time PCR, and apoptosis was evaluated by caspase-3 activity and TUNEL staining. The anti-apoptotic effect of Exendin-4 was also evaluated.

Results: Polyinosinic:polycytidylic acid transfection led to elevated expression of the genes encoding IFNα, IFNβ, CXCL10, Fas, viral receptors, and IFN-inducible antiviral effectors in MIN6 cells. Exendin-4 treatment suppressed the elevated gene expression levels and reduced polyinosinic:polycytidylic acid-induced apoptosis both in MIN6 cells and in insulin-producing cells from human induced pluripotent stem cells. Glucagon-like peptide-1 receptor, protein kinase A, and phosphatidylinositol-3 kinase inhibitors counteracted the anti-apoptotic effect of Exendin-4.

Conclusions: Polyinosinic:polycytidylic acid transfection can mimic viral infection, and Exendin-4 exerted an anti-apoptotic effect both in MIN6 and insulin-producing cells from human induced pluripotent stem cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Apoptosis / drug effects
  • Cell Differentiation
  • Cells, Cultured
  • Chemokine CXCL10 / genetics
  • Chemokine CXCL10 / metabolism
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / genetics
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Enzyme Inhibitors / pharmacology
  • Exenatide
  • Gene Expression Regulation
  • Glucagon-Like Peptide-1 Receptor / antagonists & inhibitors
  • Glucagon-Like Peptide-1 Receptor / genetics
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / metabolism*
  • Induced Pluripotent Stem Cells / pathology
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism*
  • Insulin-Secreting Cells / pathology
  • Interferon Inducers / pharmacology
  • Interferon-alpha / genetics
  • Interferon-alpha / metabolism
  • Interferon-beta / genetics
  • Interferon-beta / metabolism
  • Models, Biological*
  • Peptides / pharmacology*
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Poly I-C / genetics
  • Poly I-C / pharmacology
  • Receptors, Virus / genetics
  • Receptors, Virus / metabolism
  • Signal Transduction
  • Transfection
  • Venoms / pharmacology*
  • Virus Diseases / genetics
  • Virus Diseases / metabolism
  • Virus Diseases / pathology
  • fas Receptor / genetics
  • fas Receptor / metabolism

Substances

  • Antiviral Agents
  • CXCL10 protein, human
  • Chemokine CXCL10
  • Enzyme Inhibitors
  • FAS protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Interferon Inducers
  • Interferon-alpha
  • Peptides
  • Phosphoinositide-3 Kinase Inhibitors
  • Receptors, Virus
  • Venoms
  • fas Receptor
  • Interferon-beta
  • Exenatide
  • Cyclic AMP-Dependent Protein Kinases
  • Poly I-C

Grants and funding

This work was supported by JSPS KAKENHI Grant Number 15K09429 received by AI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.